Iron overload is a systemic disorder and is either primary (genetic) or secondary (exogenous iron administration). Primary iron overload is most commonly associated with hereditary hemochromatosis and secondary iron overload with ineffective erythropoiesis (predominantly caused by b-thalassemia major and sickle cell disease) that requires long-term transfusion therapy, leading to transfusional hemosiderosis. Iron overload may lead to liver cirrhosis and hepatocellular carcinoma, in addition to cardiac and endocrine complications. The liver is one of the main iron storage organs and the first to show iron overload. Therefore, detection and quantification of liver iron overload are critical to initiate treatment and prevent complications. Liver biopsy was the historical reference standard for detection and quantification of liver iron content. Magnetic resonance (MR) imaging is now commonly used for liver iron quantification, including assessment of distribution, detection, grading, and monitoring of treatment response in iron overload. Several MR imaging techniques have been developed for iron quantification, each with advantages and limitations. The liver-to-muscle signal intensity ratio technique is simple and widely available; however, it assumes that the reference tissue is normal. Transverse magnetization (also known as R2) relaxometry is validated but is prone to respiratory motion artifacts due to a long acquisition time, is presently available only for 1.5-T imaging, and requires additional cost and delay for off-line analysis. The R2* technique has fast acquisition time, demonstrates a wide range of liver iron content, and is available for 1.5-T and 3.0-T imaging but requires additional postprocessing software. Quantitative susceptibility mapping has the highest sensitivity for detecting iron deposition; however, it is still investigational, and the correlation with liver iron content is not yet established. 
and affects 2% of those of northern European descendancy (7) . This leads to decreased production of hepcidin, the protein responsible for regulation of iron absorption in the enterocytes (1, 2) . Other genetic diseases, such as hereditary aceruloplasminemia, ferroportin diseases, and hereditary atransferrinemia, are rare (1) .
Secondary iron overload is mostly associated with multiple red blood cell transfusions in patients with red blood cell disorders, including b-thalassemia major, sickle cell disease, myelodysplasic syndromes, Blackfan-Diamond anemia, and aplastic anemia (8) . Moreover, diseases linked with abnormal hemoglobins or thalassemia also interfere with expression of hepcidin, therefore also increasing iron overload by increased intestinal absorption. This is well demonstrated in thalassemia intermedia, in which patients can have iron overload without transfusion. Less commonly, parenteral iron administration or oral iron supplementation may also cause iron overload (2, 9) , such as in those with end-stage renal disease.
Clinically significant variants of hemoglobinopathies (including hemoglobin S, hemoglobin C, hemoglobin E, hemoglobin D, b-thalassemia, and α 0 thalassemia) are carried by 18% of the population in Africa; α-thalassemia variants are most common in Southeast Asia, Africa, and the Eastern Mediterranean region, where they are carried by 45%, 41%, and 19% of the population, respectively (10) . There is a strong correlation between sickle cell disease and thalassemia in malaria-endemic regions because abnormal red blood cells offer some level of protection against malaria (11, 12) . The high prevalence of iron overload in these regions is a major public health concern.
Patients with hemochromatosis or transfusional hemosiderosis have higher transferrin and ferritin levels and accumulation of free iron, particularly in the hepatocytes. Iron overload in the liver generates the release of reactive oxygen species (5), causing toxic effects on the cellular membrane and nuclei of the hepatocytes. Detection and grading of iron overload are critical because not treating or poorly treating it may lead to organ dysfunction and damage through oxidative cytotoxicity (1) . Iron overload in the heart can cause cardiomyopathy, which may result in decreased left ventricular ejection fraction, congestive heart failure, and ventricular arrhythmias; iron in the liver may lead to cirrhosis with increased risk of developing hepatocellular carcinoma and end-stage liver disease requiring transplant; iron in endocrine organs such as the pituitary gland may cause growth failure and in the pancreas may cause type 2 diabetes (13, 14) .
Introduction
Iron overload is a systemic disorder characterized by a high level of plasma iron and accumulation of iron in parenchymal cells in the form of ferritin and hemosiderin. The liver is the main iron storage organ (in hepatocytes and Kupffer cells) and the first to show iron overload (1) .
Oral intake of iron in a normal diet is approximately 10-20 mg/d, of which only 1-2 mg is absorbed in the proximal duodenum by the ferroportin transporters, which are regulated by the protein hepcidin (1, 2) . Plasma iron is then transported in the bloodstream by the protein transferrin (Fig 1) .
In the event of iron overload, the transferrin saturation can exceed 45% (normal range, 20%-45%), at which point non-transferrinbound iron is created, which has a high affinity for parenchymal cells, especially hepatocytes (3, 4) . Eventually, if the transferrin saturation exceeds 75%, a new form of non-transferrin-bound iron is produced-labile plasma iron-which has the potential to produce toxic reactive radicals (5). When not immediately needed, iron is stored in its ferric form (Fe 3+ ) within ferritin and eventually within hemosiderin if ferritin storage is saturated (1, 6) (Table 1) .
Iron-deposition diseases can be classified into two main categories: primary iron overload caused by genetic diseases and secondary iron overload caused by exogenous iron (Table 2) . Primary iron overload is most often associated with hereditary hemochromatosis, which is caused by mutations in the "high iron Fe" (HFE) gene. The homozygote form is the most common variant
TEACHING POINTS
■ Noninvasive quantification of iron with MR imaging is now considered the standard of care in diagnosis and monitoring of iron overload diseases.
■ Although iron overload can be seen in many organs, the liver is the main iron storage organ, the first to show iron overload, and the only one to show a linear relationship between its iron concentration and total body iron. Therefore, MR imaging for quantification of liver iron provides a good estimate of the degree of iron overload and allows prediction of the risk of complications.
■ Detection of iron overload is important owing to the risk of complications such as myocardial disease, liver cirrhosis, and increased risk of hepatocellular carcinoma development in untreated patients.
■ Annual liver iron quantification with MR imaging is recommended for patients undergoing long-term transfusion, starting at the age of initial diagnosis.
■ Preliminary results suggest that ultrashort-TE sequences may represent a viable replacement for or alternative to conventional GRE sequences for R2* estimation, for both low and high iron overload. Iron (Fe) metabolism. Absorption of oral iron intake occurs in the duodenum, near the gastroduodenal junction. Hemochromatosis is caused by a defect in the HFE gene. In hemochromatosis, iron overload is predominantly distributed in the hepatocytes in the liver and eventually in other organs, predominantly in the β cells in the pancreas and in the heart. Hemosiderosis is caused by repeated blood transfusions, typically in sickle cell disease and β-thalassemia major. In hemosiderosis, iron overload is concentrated in the reticuloendothelial system, predominantly the spleen, bone marrow, and Kupffer cells in the liver. Hemolysis in hemolytic anemias can lead to iron accumulation in the proximal convoluted tubules of the kidneys.
The liver is the organ of choice for biopsy, since liver iron content is strongly correlated with total body iron (1). Histologic grading of liver iron content is based on visual assessment of iron granules with Prussian blue stain at different magnifications. It is scored on a scale from 0 to 4, with 0 indicating absence of iron granules at 3400 magnification and 4 indicating iron visible at 310 magnification or with the naked eye (17, 18) . This method is limited by its low intraand interobserver repeatability (19, 20) .
Quantification of liver iron concentration with biochemical techniques, either with colorimetric or atomic absorption on deparaffinized tissue, constitutes the current reference method for histologic grading (18) . Biochemical methods for quantification of liver iron content have been used in most magnetic resonance (MR) imaging Serum ferritin and transferrin levels are widely used to detect body iron overload. However, the level of serum ferritin may be affected by infections and inflammation states. Further, transferrin saturation may decrease in chronic iron deficiency, inflammation states, extensive malignancy, uremia, and nephrotic syndrome. Hence, because of these biologic confounders, blood markers should be used with caution to interpret the severity of iron overload (15) .
Ultrasonography (US) does not allow detection or quantification of liver iron overload. Conventional single-energy computed tomography (CT) allows detection of iron overload by demonstrating increased attenuation of the liver parenchyma but is not sensitive or specific enough for grading or quantification of iron overload (16). validation studies (21) . Advantages of liver biopsy include the ability to evaluate multiple histopathologic changes, such as the presence and grade of liver iron, fat, inflammation, biliary disease, and fibrosis (2). However, liver biopsy has limitations, some of which are inherent to the procedure and some of which are specific to assessment of liver iron. This technique is vulnerable to sampling error because it evaluates only a small tissue specimen (19, 20) . Studies have shown that there can be great intraorgan variability in liver iron content, especially in diseased liver; therefore, the specimen may not be representative if the iron deposition is heterogeneous (22, 23) . Wood et al (24) reported that liver MR imaging is more precise than liver biopsy for assessment of total body iron because of the former's lower sampling variability.
Liver biopsy has low acceptance by patients and physicians owing to concerns about pain, potential complications, high cost, low reimbursement, and logistic issues (25, 26) . This reluctance to undergo liver biopsy is further compounded by patients' increased awareness of the existence of alternative noninvasive techniques. While risk of severe intraperitoneal bleeding is generally perceived to be low-one in 2500 to one in 10 000 biopsies (20)-bleeding risk may be a concern and may even be strictly contraindicated in these patients, as the risk of bleeding is exacerbated by low platelet counts caused by liver insufficiency or hematologic disorders (27) (28) (29) . There are other concerns about potential complications of infection, pneumothorax, hemothorax, and bowel perforation, especially if real-time image guidance is not used.
Over the past decade, technological developments have enabled MR imaging-based noninvasive techniques for quantitative assessment of liver iron overload. Many of these techniques, initially developed for research, have been adopt ed for clinical care and are now commercially available on clinical MR imaging units. Noninvasive quantification of iron with MR imaging is now considered the standard of care in diagnosis and monitoring of iron overload diseases (15) . Some sequences are further refined for assessment of severe iron overload.
In this article, we describe the clinical applications of MR imaging-based liver iron quantification, including assessment of distribution, detection, grading, and monitoring of treatment response in iron overload. We review MR imagingbased quantification techniques. For each, we discuss the physical concepts, acquisition techniques, postprocessing, advantages, and limitations. We summarize the thresholds for different levels of iron overload severity and associated complications as well as the clinical thresholds for initiating 
Clinical Indications for Liver Iron Quantification

Distribution of Iron Overload
In hereditary hemochromatosis, iron overload in the abdomen initially occurs in the liver and pancreas. Non-transferrin-bound iron has a high affinity for hepatocytes (1, 5) . In transfusional hemosiderosis, iron overload occurs in the reticuloendothelial system. This typically occurs by uptake of free iron by macrophages in the spleen and bone marrow and Kupffer cells in the liver (1) .
In hemolytic anemia such as sickle cell disease, iron overload follows the same distribution as in transfusional hemosiderosis. However, the spleen may be small owing to autosplenectomy, and the renal cortex may also demonstrate iron overload owing to intravascular hemolysis of red blood cells and accumulation of unbound hemoglobin in the proximal convoluted tubules through filtration in renal glomeruli (27, (30) (31) (32) . Cortical kidney iron overload resulting from chronic hemolysis is common in sickle cell disease but not in thalassemia (33). Interestingly, kidney iron overload decreases in patients with sickle cell disease undergoing long-term transfusion who are receiving chelation therapy (33). However, in practice many variants are observed, as patients undergoing severe long-term transfusion often develop pituitary and pancreatic iron overload (34, 35) .
We illustrate the theoretical distribution of iron overload in abdominal organs for hemochromatosis, transfusional hemosiderosis, and sickle cell disease (Fig 2) . Although iron overload can be seen in many organs, the liver is the main iron storage organ, the first to show iron overload, and the only one to show a linear relationship between its iron concentration and total body iron (36, 37) . Therefore, MR imaging for quantification of liver iron provides a good estimate of the degree of iron overload and allows prediction of the risk of complications.
Detection of Iron Overload
Clinical indications for iron detection with MR imaging include abnormally elevated ferritin or iron saturation, a high number of red blood cell transfusions, or a family history of hemochromatosis after genetic testing has been done, namely the search for C282Y and H63D mutations in the HFE gene. However, these genetic analyses do not cover all cases of hemochromatosis, and if the clinical history raises a suspicion of hereditary hemochromatosis, MR imaging should be performed to assess the severity and distribution of iron overload (7) .
Detection of iron overload is important owing to the risk of complications such as myocardial disease, liver cirrhosis, and increased risk of hepatocellular carcinoma development in untreated There is pancreatic fat infiltration with signal drop on the out-of-phase images (2.3, 6.9, 11.5, and 16.1 msec). Middle: Moderate iron overload in a 27-year-old man with sickle cell disease. Low liver signal intensity is best seen with an intermediate TE (6.9 msec). R2* = 140 sec −1 . There is marked iron overload in the spleen, which causes significant blooming on the longer TE images, limiting evaluation of the pancreatic tail and upper pole of the left kidney. Bottom: Severe iron overload in a 38-year-old woman with sickle cell disease. Low liver signal intensity is best seen with the shortest TE (2.3 msec). R2* = 310 sec −1 . There is renal cortical iron overload, suggesting recent intravascular hemolysis.
patients. Hence, it is critical to detect liver iron overload at an early stage and initiate treatment (discussed later) before the advent of complications (1).
Grading of Iron Overload
Grading the severity of iron overload in hemochromatosis and transfusional hemosiderosis (Fig 3) is helpful to guide initiation of proper treatment and help prevent future complications of untreated iron overload. Grading the degree of iron overload (as mild, moderate, or severe) can be performed subjectively or quantitatively (18) . Subjective assessment of liver iron overload can be performed by comparing the signal intensity of the liver to that of other reference structures less prone to iron overload (such as paraspinal muscles) (38, 39) . Alternately, quantitative assessment is performed by measuring the degree of iron overload using one of the MR imaging-based quantification techniques discussed later. The measurement can then be converted to degree of iron overload on the basis of clinical thresholds.
Monitoring Treatment Response
Monitoring response to treatment in iron overload is required to adjust the most appropriate treatment with the least adverse effects. In hemochromatosis, the decision to initiate phlebotomy or adjust its frequency is typically based on the serum ferritin level. However, use of the serum ferritin level has some limitations: the initial serum ferritin level at the time of diagnosis does not accurately predict the number of phlebotomies required to reach normal liver iron concentration levels (40) , and the subsequent serum ferritin levels do not decrease linearly with phlebotomy (41) . While liver biopsy may in theory be used to monitor iron content mobilized by phlebotomies, it is usually reserved for staging of liver fibrosis in patients with hemochromatosis (42) . Hence, MR imaging-based liver iron quantification has been proposed as a noninvasive alternative to liver biopsy both to predict the presence of fibrosis (43) and to monitor the progress of phlebotomy in hemochromatosis (29) . In transfusional hemosiderosis, the decision to initiate chelation therapy is based on a combination of serum ferritin level and liver iron content, which may be estimated with MR imaging-based techniques (44) . The literature shows that serum ferritin level is an unreliable predictor of total body iron stores in thalassemia and sickle cell anemia (45, 46) . In patients with transfusional hemosiderosis, MR imaging relaxometry is superior to liver biopsy for monitoring liver iron content (24) .
In thalassemia, transfusion is not the only physiologic event leading to iron overload. Ineffective erythropoiesis is an important factor leading to increased iron absorption. This physiologic event alone can lead to iron overload; thus, the numeration of blood transfusions alone cannot be used to identify the population at risk for iron overload.
Iron deposition in different organs can vary between patients, and MR imaging remains the only modality to allow evaluation of the distribution of nonhepatic iron stores (44) . Moreover, sickle cell disease is known to cause an inflammatory state in which ferritin level is increased. Furthermore, organ iron deposition is directed only at patients who have received at least eight units of packed red blood cells.
The type of chelation and dose do not allow prediction of the efficacy of a treatment with enough certitude, and monitoring of organ deposition remains necessary considering the large variability in efficacy between individuals. Further, partial or absent response to treatment may indicate poor compliance with oral chelation therapy, which may require the addition of intravenous chelation therapy. Diseases leading to iron overload often cannot be treated curatively. Therefore, these patients are typically followed for years, and repeated liver biopsy is not an acceptable option for assessment of treatment response because of the reasons discussed earlier.
Qualitative and Quantitative Methods for Liver Iron Evaluation Blood Tests
Iron overload is often initially detected on the basis of an abnormal serum transferrin level. Serum ferritin level generally increases with total body iron load, but this finding is not specific (47) ; ferritin level may be elevated in alcohol abuse, metabolic syndrome, or sideroblastic anemia, to name only a few conditions (48, 49) . Ferritin is an acute-phase protein, and as such its level can vary widely owing to inflammation, infection, liver damage caused by steatohepatitis or liver fibrosis, vitamin C levels, and even chelation therapy (47, 50) .
Therefore, serum ferritin is not an appropriate marker for diagnosis and monitoring of liver iron overload (15) . Serum ferritin levels above 1000 µg/L warrant further evaluation to identify the cause of the iron overload, especially in the setting of hemochromatosis gene mutation, because such high levels of ferritin correlate with increased risk of death. The correlation of blood markers with iron body content is not as good as that of measurement with liver biopsy or MR imaging-based quantification (15) .
Ultrasonography
US cannot be used to evaluate liver iron overload, whether qualitatively or quantitatively (16) . However, it can be used to detect complications from iron overload, such as liver fibrosis, cirrhosis, portal hypertension, or hepatocellular carcinoma.
Computed Tomography
Conventional (single-energy) CT may allow detection of liver iron overload by showing increased attenuation but is not sensitive or specific. At nonenhanced CT, the attenuation of normal hepatic parenchyma usually ranges between 55 and 65 HU. Beyond that threshold, hepatic iron overload may be suspected (51) . However, this threshold is not specific to iron overload, as other pathologic conditions can manifest with increased liver attenuation, such as Wilson disease, glycogen-storage diseases, or long-term amiodarone administration (51, 52) . Additionally, CT is associated with radiation and thus less appropriate for long-term monitoring, especially in young patients requiring repeated imaging throughout their lives (2) . Dual-energy CT is an emerging technique for iron quantification that requires comparison of liver attenuation on images obtained at two different kilovolt peak (kVp) settings with those of standardized cylinders of known iron concentration. With this method, reducing the kilovolt peak and kilo-electron volt (keV) values will show an increase in liver attenuation in the presence of iron overload and a decrease in the presence of steatosis. Further validations are still necessary before clinical application (53, 54) .
Biomagnetic Susceptometry
Biomagnetic liver susceptometry using a superconducting quantum interference device (SQUID) is an extremely sensitive technique that permits measurement of very small magnetic field variations, such as those induced by the presence of superparamagnetic liver iron. The correlation between liver iron content measured with biomagnetic susceptometry and that measured with liver biopsy has been proved to be excellent, and this technique is often considered the noninvasive reference standard for liver iron quantification (55) . However, only a limited number of these devices are available worldwide, making this approach unavailable to most patients.
MR Imaging-based Iron Quantification Techniques
In this section, we review basic physics concepts relevant to MR imaging-based iron quantification. For each technique, we discuss the protocol, technical implementation, advantages, and limitations.
MR Imaging Physical Concepts
The presence of liver iron has multiple effects on the MR imaging signal, and several contrast mechanisms can be exploited to gain sensitivity to the presence of iron. For instance, liver iron, typically present in the form of ferritin or hemosiderin, will have an influence on the relaxation times of the liver parenchyma, most notably T2 and T2*, and will also lead to a local alteration of the magnetic field, which can also be detected using phase-based methods such as quantitative susceptibility mapping.
T2 represents the time constant of the intrinsic decay of the transverse magnetization from spinspin interactions, while T2* also incorporates effects from local magnetic field inhomogeneities: 1/T2* = 1/T2 + 1/T2', where T2' is the additional contribution from field inhomogeneities (56) . T2 and T2* can also be represented as relaxivity rates, such that R2 = 1/T2, R2* = 1/T2*, and R2* = R2 + R2'. For example, a T2* of 5 msec would correspond to an R2* of 200 sec −1 (ie, R2* = 1/0.005 sec). The presence of liver iron will also lead to shortening of the longitudinal relaxation time constant T1, although this effect is generally weaker and not typically used for diagnosis of iron overload.
The superparamagnetic effect of ferritin and hemosiderin creates a local susceptibility-induced contribution to the local magnetic field that results in faster decay of the traverse magnetization (Fig  4) , although the exact physical mechanisms involved differ for T2 and T2* relaxation (1). In both cases, the signal intensity on T2-and T2*-weighted images decreases with an increase in the iron concentration, as a result of shorter T2 and T2* constants (Fig 5) and an increase in R2 and R2*.
In clinical practice, gradient-echo (GRE) sequences are often used for their increased sensitivity to magnetic susceptibility ( Table 3) . As opposed to the presence of microscopic fat, which demonstrates a decrease in signal intensity on outof-phase GRE images compared with in-phase images, the presence of liver iron overload will show decreased signal intensity on in-phase images compared with out-of-phase images. This phenomenon is due to the fact that in-phase images are typically acquired using a longer echo time (TE) than outof-phase images, which leads to further decay of the signal secondary to the reduction in T2*.
Comparison of MR Imaging-based Iron Quantification Techniques
For each of the iron quantification techniques, we discuss acquisition techniques, acquisition protocols, postprocessing, advantages, and limitations. A summary of the key acquisition parameters of the MR imaging protocols is provided (Table 4) (21, 38, (57) (58) (59) , as well as a summary of the advantages and limitations of each technique (Table 5) (2,59,60 ).
Liver-to-Muscle Signal Intensity Ratio
Concept.-The GRE-based signal intensity ratio technique is based on observation of a signal intensity decrease from T2* shortening in the presence of liver iron overload in comparison with the signal intensity of a reference tissue (assumed to be unaffected by iron content), typically the paraspinal muscles. The signal intensity of normal liver parenchyma (ie, without iron overload) should always be higher than that of the paraspinal muscles. Therefore, a hypointense liver relative to the paraspinal muscles indicates iron overload. This is assessed semiquantitatively by measuring the liver-to-muscle signal intensity ratio (2, 38) .
In severe iron overload, the signal intensity of the liver is lower than that of the paraspinal muscles even with sequences with limited sensitivity to iron overload (ie, T1-weighted and proton-density-weighted sequences). In moderate iron overload, lower signal intensity of the liver relative to that of the paraspinal muscles is seen with sequences that are moderately sensitive to iron overload (ie, T2*-weighted sequences with intermediate TE). In mild iron overload, lower signal intensity of the liver relative to that of the paraspinal muscles is seen with sequences that are most sensitive to iron overload (ie, heavily T2*-weighted sequences with long TE) (38) .
Protocol.-At 1.5 T, five GRE sequences are performed during separate breath holds with a constant repetition time of 120 msec, a constant flip Note.-PD = proton density, SI = signal intensity.
angle of 20°, and varying TE to achieve different weighting: a T1-weighted sequence with TE of 2 msec, a proton-density-weighted sequence with TE of 4 msec, and T2*-weighted sequences with increasingly long TEs of 9 msec, 14 msec, and 19 msec. This protocol was updated in September 2017, with small modifications made to the first and last sequences since an earlier version (38) .
For this protocol, a body coil should be used to ensure homogeneous transmission and reception of the signal to optimize image quality and minimize artifacts, since surface coils tend to produce higher signal intensity close to the coil (38) . With the signal intensity ratio technique, out-ofphase TEs are intentionally avoided because this would cause ambiguity in the interpretation of Note.-PDW = proton-density-weighted, T1W = T1-weighted, TR = repetition time, T2*W = T2*-weighted, T2*+W = T2*+-weighted, T2*++W = T2*++-weighted. 
msec (T1-weighted) (a), 4.6 msec (proton-density-weighted) (b), 9.2 msec (T2-weighted) (c), 13.8 msec (T2+-weighted) (d), and 18.3 msec (T2++-weighted) (e).
Three ROIs were drawn in the liver (yellow circles) and one in each paraspinal muscle (red circles) for each of the five sequences. Associated splenomegaly is seen. Liver iron content was 160 µmol/g ± 50 (8.9 mg/g dry weight ± 2.8) according to the Rennes protocol.
signal drop, which could not be unequivocally attributed to iron or fat overload. The acquisition time is 15 seconds per sequence, and total examination time is about 2 minutes (2). Acquisition protocols are provided online for MR imaging field strengths of 1.0 T, 1.5 T, and 3.0 T (38,61). The author who originally developed this technique recently demonstrated the feasibility of the signal intensity ratio approach at 3.0 T (39). Three of them are drawn in the liver parenchyma, excluding vascular structures, and one is drawn in each paraspinal muscle (Fig 6) . The process is repeated with the five MR imaging sequences described earlier (Fig 7) (61) .
Postprocessing.-The values obtained with measurement of the ROIs are used to compute five different liver-to-muscle signal intensity ratios, which are then analyzed with the algorithm developed by Gandon et al (38) and implemented on a free web-based calculator hosted by the University of Rennes (Fig 8) (61) .
Advantages.-This is the simplest method for quantification of liver iron overload, requiring the least amount of postprocessing. The technique can be implemented on a wide array of MR imaging units from different vendors. The acquisition parameters required and the postprocessing calculations are provided free by the developers of the technique. Furthermore, this technique at 3.0 T will be more sensitive to milder liver iron overload (2,38,39).
Limitations.-This technique is not accurate for severe iron overload exceeding 350 µmol/g dry weight (19.5 mg/g dry weight) and tends to overestimate mild and moderate liver iron overload. This is why use of the signal intensity ratio method-although still available online-is discouraged by the developer of the technique, who now recommends use of a multiecho GRE protocol and provides a free Java application that permits off-line calculation of liver iron content on the basis of the signal intensity ratio and T2* (38, 61) . Further, the technique is dependent on the assumption that the reference tissue is normal. While paraspinal muscles should not be affected by iron overload, muscle atrophy and fat infiltration, especially in elderly patients, may confound the T1 and T2* of the muscles (38, 39) . Spatial inhomogeneity of signal from B 0 or B 1 inhomogeneity effects at 3.0 T may represent an additional limitation. The liver-to-muscle signal intensity ratio technique requires measurement of the signal intensity with three ROIs in the liver (yellow circles), excluding vascular structures, and one ROI in each paraspinal muscle (red circles) with five MR imaging sequences, in which repetition time and flip angle are held constant while varying TE to alter the T1 and T2* weighting. These values are used to compute five different liver-to-muscle signal intensity ratios, which are then analyzed with the algorithm developed by Gandon et al (38) and provided on the website of the University of Rennes.
T2 and R2 Relaxometry
Concept.-Although the precise mechanism by which T2 and R2 relaxometry is affected by the presence of iron has not been clearly established, two mechanisms have been proposed to explain T2 shortening in the presence of iron overload. The first theory suggests that proton exchange between bulk water and exchangeable protons on the surface of the ferritin core affects the relaxation rate of the protons locally (62) . The second theory explains that hemosiderin clusters induce a magnetic field inhomogeneity, which causes a relaxation mechanism based on diffusion of protons (63) . These two mechanisms may contribute to decrease of T2 and increase of R2 in the presence of iron. The technique known as R2 relaxometry has been validated by St Pierre et al (21) and is approved by the U.S. Food and Drug Administration (FDA). It is commercialized as FerriScan (Resonance Health) (64).
Protocol.-At 1.5 T, R2 relaxometry requires a multisection single spin-echo sequence during free breathing to obtain axial images with repetition time of 2500 msec, TE every 3 msec from 6 msec to 18 msec (at 6, 9, 12, 15, and 18 msec), flip angle of 90°, section thickness of 5 mm, matrix size of 256, and field of view between 350 and 400 mm, depending on the patient's habitus (21) . A bag of saline solution or Ringer solution is placed in the field of view to serve as an internal control.
Measurement Method.-To develop the calibration curve that links the R2 measurement with the liver iron concentration, the developers of this technique selected an ROI covering the right liver lobe on the largest axial section of the liver.
The details of the measurement technique are not provided for the commercial implementation of R2 relaxometry (21) .
Postprocessing.-Postprocessing requires transfer of images acquired according to the recommended protocol of Resonance Health. A weighted biexponential model that includes corrections for signal gain drift, noise bias, and radiofrequency field inhomogeneities is fitted to the image signal intensities measured at each TE to calculate R2, then the liver iron content is estimated by using the calibration curve developed by St Pierre and colleagues (21, 37, 65) . The image analysis is performed remotely, and results are returned with a color parametric map of R2 (37, 64) .
Advantages.-R2-measured liver iron content correlates well with biopsy liver iron content in a nonlinear fashion. Images are acquired during free breathing, which may be more comfortable for patients unable to hold their breath, such as young children and fragile patients. The company provides assistance for calibration of the MR imaging unit and quality control, thus making this approach more convenient for centers with a lower volume of examinations or less familiarity with the physical concepts (21, 37, 64) .
Limitations.-Because of the nonlinear relation, liver iron content values measured with R2 relaxometry become more variable in higher iron overload when liver iron content is over 20 mg/g dry weight, making liver iron content calculation less precise. FerriScan is the only commercially available R2 relaxometry iron quantification technique. Coexisting liver steatosis is problematic, since fat saturation is not used. It requires a long acquisition time, up to 20 minutes while freely breathing, making it prone to respiratory motion artifacts and thus not practical in the setting of restrained resources of equipment and time (37) . The lack of fat saturation of the subcutaneous fat can also cause a ghosting effect in the liver with respiratory motion.
It also requires additional cost and delay for the data analysis, with the company's target time being within 2 business days (64) . Therefore, post hoc addendums to radiology reports may be made after the company's report is available.
T2* and R2* Relaxometry
Concept.-As explained earlier, liver parenchymal iron overload causes T2* to decrease and R2* to increase owing to a combination of the T2 (R2) effects and the microscopic inhomogeneities introduced in the main magnetic field (B 0 ) by the superparamagnetic properties of hemosiderin clusters (58) .
Protocol.-In the original description of the technique, GRE sequences with multiple breath holds were used to obtain axial images with repetition time of 25 msec, TEs every 0.25 msec from 0.8 msec to 4.8 msec, flip angle of 20°, section thickness of 15 mm, matrix size of 64 3 64 and field of view of 48 3 24 mm, depending on the patient's habitus, and bandwidth of 83 kHz (58) . More recently, single breath-hold multiecho GRE sequences have been widely adopted, both in research and the clinical setting (22, 66) . Multiple variants of multiecho protocols have been described in the literature. However, there has not been consensus on the recommended acquisition parameters for assessment of R2* (30, 67, 68) . Measurement Method.-Wood et al (58) measured the R2* from a single midhepatic section by drawing an ROI following the boundaries of the liver and excluding hilar vessels to obtain an R2* map. To use this equation to estimate the MR imaging-based liver iron content, acquisition protocols should be similar to the one described by Wood et al (58) . There have been some other calibration curves for liver iron content and R2* proposed in the past few years, all fairly similar (30, 67, 68) .
Advantages.-In multiple studies, R2* has been demonstrated to have a linear correlation with biopsy-determined liver iron content, which makes R2* relaxometry a reliable technique for noninvasive liver iron overload quantification (58).
Multiecho GRE MR imaging techniques are more practical, as they are faster and permit simultaneous quantification of liver steatosis and iron overload in a single breath hold, thus reducing motion artifacts and optimizing acquisition time (22, 66) . Liver iron content can be estimated at 1.5 T and 3.0 T, and this technique enables detection of a wide dynamic range, from mild (Fig 9) to severe.
Limitations.-Use of 3.0-T imaging will reduce the upper measurable range limit of liver iron content by two owing to the faster decay of the signal. The R2* at 3.0 T has been shown to be twice that at 1.5 T (2,58). At 1.5 T, R2* relaxometry has been shown to be limited in very severe iron overload with liver iron content higher than 30 mg/g dry weight (37) . The postprocessing algorithms are commercially available only as a purchaseable option and may not be universally available. A limitation of this technique is the other contributors to B 0 inhomogeneity, such as air and metal, and dependence on voxel geometry (69).
Quantitative Susceptibility Mapping
Concept.-The presence of a local susceptibility source such as ferritin or hemosiderin leads to an augmentation of the local magnetic field, which has an impact on the measured phase of a GRE sequence. Using an acquisition with two or more echoes, the local magnetic field can be estimated, and the inverse problem relating the measured magnetic field distribution to the underlying susceptibility distribution can be solved (70) .
Protocol.-Abdominal quantitative susceptibility mapping can be performed using a three-dimensional breath-hold multiecho GRE sequence. With appropriate parameters, such an acquisition can be used to simultaneously perform chemical shift-encoded water/fat separation, T2*/R2* mapping, and B 0 field mapping, from which a quantitative susceptibility map can be reconstructed (59, 71) .
Measurement Method.-After calculation of the quantitative susceptibility map, a local relative susceptibility value (ΔB 0 ), generally expressed in parts per million (ppm), can be extracted from an ROI. That susceptibility value can be related to the liver iron content.
Postprocessing.-Calculation of a quantitative susceptibility map requires several postprocessing steps (Fig 10) . The first step is generally to estimate a B 0 field map from the acquired data. In the case of abdominal applications, for which the presence of fat is expected, this is ideally performed using a chemical shift-encoded reconstruction, to separate the contribution of susceptibility sources from the contribution of chemical shift effects in the measured phase.
The magnetic field from local sources is then estimated from the overall magnetic field, and the underlying susceptibility distribution is reconstructed by solving the corresponding inverse problem. In practice, some of these steps can be combined. The inversion from magnetic field to susceptibility typically requires anatomic regularization, given the ill-posed nature of the problem (59, 70, 71) .
Advantages.-Quantitative susceptibility mapping is potentially the most direct and most sensitive MR imaging technique for detection of iron deposition. Furthermore, all acquisitions are typically performed in a single breath hold, reducing to a minimum the risk of motion. Recent algorithms can correct for the presence of fat. Additionally, susceptibility values can be compared regardless of the field strength (Fig 11) . accuracy and reproducibility will be needed to establish it as a future valuable liver iron quantification technique (2, 59) .
Clinical Applications of MR Imagingbased Iron Quantification Techniques
MR imaging-based iron quantification techniques may be used to assess the distribution and severity of disease. In addition, these techniques are required to monitor liver iron overload for adjustment of phlebotomy (in hereditary hemochromatosis) and to evaluate response to or compliance with chelation therapy in hereditary hemochromatosis and transfusional hemosiderosis (mainly b-thalassemia and sickle cell disease).
Hemochromatosis is a genetic disease caused by genetic mutations in the HFE gene, leading to increased absorption of iron in the duodenum and iron overload, primarily in the liver, heart, pancreas, and pituitary gland (72, 73) (Fig 12) . Since physiologic iron excretion occurs by cellular exfoliation, menstruation, or other causes of bleeding, the ability to eliminate excess iron is limited (74) . Hence, the main goal of treatment is to increase iron excretion. Since patients with hemochromatosis do not have blood dyscrasia, phlebotomies may be performed to reduce iron overload and prevent complications. Initiation and adjustment of the frequency of the phlebotomies are currently based on the ferritin level, aiming for ferritin levels between 50 and 100 µg/L, according to the practice guideline of the American Association for the Study of Liver Diseases (AASLD) ( Table 6 ) (15).
b-thalassemia major is a genetic disease caused by genetic mutations, leading to severe anemia requiring repeated transfusions; otherwise death usually occurs in late childhood. Cardiac complications are the leading cause of mortality among patients who are not treated efficiently (15, 75) . Early treatment and monitoring are thus critical to minimize those important potential complications. The primary treatment of b-thalassemia major consists of blood transfusion, which is needed repeatedly to improve anemia and suppress ineffective erythropoiesis. However, while long-term transfusion prevents complications of b-thalassemia, it also leads to accumulation of iron, which is mainly stored in the reticuloendothelial system (Fig 13) .
Chelation therapy is therefore required in patients who develop iron overload to prevent toxic effects associated with large amounts of exogenous iron. These medications bind iron in the body to be excreted in the urine and/or stool. Deferoxamine, deferiprone, and deferasirox are the principal medications used.
Deferoxamine, the chelator that has been used for decades and is thus the best known, is administered subcutaneously or intravenously by the patient him-or herself at least 4 days a week for 8-12 hours, leading to compliance problems due to the high cost of the material needed, the cumbersome tubing and pump, and possible local complications such as infections and pain at the injection site. Toxic reactions to this medication may lead to retinal, auditory, and sensory neural damage.
Deferiprone, an oral chelator, is taken three times a day, and patients are generally more compliant than with intravenous treatment. The most common side effects are gastrointestinal (such as abdominal discomfort or pain, nausea, and emesis). Myalgia and joint pain are also reported, resolving with medication cessation. More serious complications include variable degrees of neutropenia, which could be as severe as agranulocytosis, which is usually reversible when medication . The liver iron concentration according to the Rennes protocol (not shown) was 160 µmol/g ± 50 (8.9 mg/g dry weight ± 2.8), which indicated moderate iron overload.
is stopped but is still potentially deadly. For this reason, patients must be followed regularly with complete blood cell counts to identify cases of agranulocytosis.
Deferasirox, an oral chelator, is taken only once daily and may cause gastrointestinal side effects. Hepatic and renal failure have been reported; thus, this treatment is contraindicated in patients with prior liver or renal dysfunction.
Combinations of different chelators are often needed to achieve optimal control of iron overload. In North America, patients usually have to choose between deferiprone and deferasirox, the latter being most frequently chosen. Differential efficacy according to site of iron overload has been documented, with deferiprone preferentially suggested for iron overload of the heart, mainly in thalassemia patients (27) . Monitoring and adjustment of chelation therapy are based on liver iron concentration as assessed with MR imaging. Monitoring of iron overload is recommended starting in early childhood and is necessary all life long, since b-thalassemia major is not a curable disease (27, 29) .
The same principles apply to sickle cell disease, which is a genetic disorder of the hemoglobin, leading to abnormal red blood cells causing hemolytic anemia. In addition to iron accumulation in the reticuloendothelial system, these patients may also demonstrate iron overload in the renal cortex owing to the hemolytic component of the disease. Other hereditary anemias, such as Blackfan-Diamond anemia, also necessitate long-term blood transfusions, leading to iron overload at a young age with subsequent risk of cardiac toxic effects (35) .
Monitoring of chelation therapy is based on liver iron content as assessed with MR imaging instead of liver biopsy (Table 7) . Annual liver iron quantification with MR imaging is recommended for patients undergoing long-term transfusion, starting at the age of initial diagnosis (15, 35) .
We provide a summary of the clinical thresholds for serum analysis and MR imaging-based quantification for different levels of iron overload severity (Table 8) . We used a linear calibration equation (Wood et al [58] ) to calculate the T2* and R2* from the threshold values of liver iron content used in treatment algorithms for iron overload pathologic conditions (72) .
Future Directions
Ultrashort-TE Sequences
Inability to accurately quantify very severe iron overload owing to very short T2* is a limitation of commercially available MR imaging-based iron quantification techniques. This constraint is exacerbated at higher field strength owing to faster T2* decay (twice as fast at 3.0 T as at 1.5 T) (76) . When iron overload is very severe, with levels over 25 mg/g dry weight at 1.5-T imaging, corresponding to T2* of 1 msec or less, the signal drops below the noise floor, leading to overestimation of T2*-and thus underestimation of iron overload-owing to inaccurate curve fit (Fig 14) .
Ultrashort-TE sequences with TE as low as 0.1 msec are achievable and would permit quantification of massive iron overload, even at 3.0 T. In comparison, the shortest TE achievable with current GRE sequences is in the range of 0.8 msec. Preliminary results suggest that ultrashort-TE sequences may represent a viable replacement for or alternative to conventional GRE sequences for R2* estimation, for both low and high iron overload (76) .
Multiparametric Assessment
Chronic liver diseases are characterized by the concomitant presence of pathologic changes, including liver fat, iron, inflammation, biliary disease, and fibrosis (77) . Further, the coexistence of several pathologic changes may act as a confounder to liver iron quantification, affecting the R2 or R2* of tissue. Eventually, multiparametric techniques will be required to assess each of these pathologic parameters and control these biologic confounders.
Hence, a comprehensive multiparametric quantitative MR imaging protocol may include elastography sequences for assessment of liver 
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Corresponding R2* map shows unreliable R2* values in the liver ( * ) and severe iron overload in the spleen (straight arrow), pancreas (curved arrow), and bone marrow (arrowhead). R2* quantification is unreliable because the signal is below the noise floor owing to very severe iron overload. There is no iron overload in the renal cortex. Also note the signal drop between in-phase acquisition (b) and out-of-phase acquisition (a), indicating fat in the bone marrow, thus contributing to some degree to the low signal intensity seen in the bone marrow on the out-of-phase images. fibrosis (77) and multiecho chemical shift-encoded GRE sequences for simultaneous assessment of proton-density fat fraction (PDFF) for liver steatosis quantification and R2* for liver iron quantification within a single breath hold (Fig 15) (22, 66, 78) . Proton-density fat fraction is a biomarker that has been validated for accurate and precise assessment of liver steatosis across different systems (79, 80) . Ultimately, combining several parameters may improve classification accuracy and lead to better diagnostic performance than use of single parameters (81, 82) .
Conclusion
Iron overload potentially leads to end-organ damage, with higher prevalence of liver (cirrhosis, hepatocellular carcinoma), endocrine, and cardiac complications. Therefore, detection and quantification of liver iron overload are critical to initiate treatment and prevent complications in hereditary hemochromatosis and transfusional hemosiderosis. Various MR imaging techniques, each with their respective advantages and limitations, have been developed for liver iron quantification. Because of the noninvasiveness and accuracy of these techniques, MR imaging-based liver iron quantification has become part of the standard of care in diagnosis and monitoring of iron overload diseases. In the near future, multiparametric quantitative protocols will permit simultaneous assessment of liver iron overload, as well as coexistent fat and fibrosis. 
